Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes
Clinical Infectious Diseases · 10.04.2024 · 78 (4) · 983-990
DOI: 10.1093/cid/ciad506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 26.08.2023. Verfasst von Marion G Peters und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Abbott, Gilead Sciences, GlaxoSmithKline.
Abstract (Originalsprache)
Chronic hepatitis B, a major cause of liver disease and cancer, affects >250 million people worldwide. Currently there is no cure, only suppressive therapies. Efforts to develop finite curative hepatitis B virus (HBV) therapies are underway, consisting of combinations of multiple novel agents with or without nucleos(t)ide reverse-transcriptase inhibitors. The HBV Forum convened a webinar in July 2021, along with subsequent working group discussions to address how and when to stop finite therapy for demonstration of sustained off-treatment efficacy and safety responses. Participants included leading experts in academia, clinical practice, pharmaceutical companies, patient representatives, and regulatory agencies. This Viewpoints article outlines areas of consensus within our multistakeholder group for stopping finite therapies in chronic hepatitis B investigational studies, including trial design, patient selection, outcomes, biomarkers, predefined stopping criteria, predefined retreatment criteria, duration of investigational therapies, and follow-up after stopping therapy. Future research of unmet needs are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Northwestern University, Chicago, Illinois, USA.
- Department of Medicine, School of Clinical Medicine & State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
- Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Aligos Therapeutics, Clinical Development Consultant, San Francisco, California, USA.
- Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Department of Pathophysiology and Transplantation, CRC "A. M. and A. Migliavacca" Center for Liver Disease, University of Milan, Milan, Italy.
ORCID-Profile: Marion G Peters
Förderung
- Abbott
- Gilead Sciences
- GlaxoSmithKline
- Roche
Zitieren
APA
Peters, M. G., Yuen, M. F., Terrault, N., Fry, J., Lampertico, P., Gane, E., Hwang, C., Stamm, L. M., Leus, M., Maini, M. K., Mendez, P., Lonjon-Domanec, I., Berg, T., Wang, S., Mishra, P., Donaldson, E., Buchholz, S., Miller, V., & Lenz, O. (2024). Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes. Clinical Infectious Diseases, 78(4), 983-990. https://doi.org/10.1093/cid/ciad506
Vancouver
Peters MG, Yuen MF, Terrault N, Fry J, Lampertico P, Gane E, et al. Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes. Clinical Infectious Diseases. 2024;78(4):983-990. doi:10.1093/cid/ciad506
BibTeX
@article{Peters2024,
author = {Peters, Marion G and Yuen, Man-Fung and Terrault, Norah and Fry, John and Lampertico, Pietro and Gane, Ed and Hwang, Carey and Stamm, Luisa M and Leus, Mitchell and Maini, Mala K and Mendez, Patricia and Lonjon-Domanec, Isabelle and Berg, Thomas and Wang, Su and Mishra, Poonam and Donaldson, Eric and Buchholz, Stephanie and Miller, Veronica and Lenz, Oliver},
title = {Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes},
journal = {Clinical Infectious Diseases},
year = {2024},
volume = {78},
number = {4},
pages = {983--990},
doi = {10.1093/cid/ciad506}
}
EUVIMED